| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Hill Stephen A is a Director at Cellectar Biosciences, Inc. with holdings across 3 companies. Recent SEC Form 4 filings include 3 buys and 3 sells.
Estimated insider holdings value: $85K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2020 | CLRB Cellectar Biosciences, Inc. | Director | Buy | 18,000 | $1.08 | $19,438.20 | New | |
| Nov 29, 2018 | CLRB Cellectar Biosciences, Inc. | Director | Sell | 992 | $2.21 | $2,192.41 | -94.9% | |
| Dec 29, 2017 | LPCN Lipocine Inc. | Director | Sale+OE | 1,250 | $3.47 | $4,341.50 | -19.2% | |
| Apr 20, 2016 | CLRB Cellectar Biosciences, Inc. | Director | Buy | 9,390 | $2.12 | $19,906.80 | +1,772% | |
| Dec 17, 2015 | GYRE Gyre Therapeutics, Inc. | Director | Buy | 5,000 | $2.03 | $10,150.00 | +31.8% |